Instructions for Authors

Shortcuts

Submission Checklist

Please:

  1. read the Aims & Scope to gain an overview and assess if your manuscript is suitable for this journal;
  2. use the Microsoft Word template or LaTeX template or Free Format Submission to prepare your manuscript;
  3. make sure that issues about publication ethics, research ethics, copyright, authorship, figure formats, data and references format have been appropriately considered;
  4. Ensure that all authors have approved the content of the submitted manuscript.
  5. Authors are encouraged to add a biography (optional) to the submission and publish it.

Manuscript Submission Overview

Types of Publications

Cancers publishes the highest quality of Research Articles, Reviews, Perspectives and Editorials related to the care of patients with cancer such as clinical trials. Cancers adopts the WHO’s definition of Clinical Trial: “Any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes”. We only publish Clinical Trials that are already registered at Primary Registries recommended by the WHO. Prospective trial registration (registration before the clinical trial starts) is required for trials that started after ICMJE recommendations took effect on July 1, 2005. For those clinical trials that started before 1 July 2005, retrospective registration may be considered.

Manuscripts submitted to Cancers should neither be published previously nor be under consideration for publication in another journal. The main article types are as follows:

  • Articles: Original research manuscripts. The journal considers all original research manuscripts, provided that the work reports scientifically sound experiments and provides a substantial amount of new information, e.g., research articles using only one cell line for the experiments will not be considered for publication (experiments need to be repeated on 1-2 more cell lines); authors should consider in vivo studies using orthotopic or transgenic models to validate gene function; for all Western blot figures, densitometry readings/intensity ratio of each band should be included; the whole Western blot showing all bands and molecular weight markers should be included in the Supplementary Materials; gene silencing experiments should use at least two gene-specific siRNAs, etc.

    Authors should not unnecessarily divide their work into several related manuscripts, although short communications of preliminary, but significant, results will be considered. Quality and impact of the study will be considered during peer review.

    Full experimental details must be provided so that the results can be reproduced. Cancers requires that authors publish all experimental controls and make full datasets available where possible (see the guidelines on Supplementary Materials and references to unpublished data).

    Articles should have a main text of around 3000 words at minimum and should have more than 30 references. Cancers has no restrictions on the maximum length of research manuscripts, provided that the text is concise and comprehensive.

  • Reviews: These provide concise and precise updates on the latest progress made in a given area of research. Systematic reviews should follow the PRISMA guidelines. Review articles should be comprehensive and submitted by authors who are in the field. The main text of review papers should be around 4000 words at minimum and include at least two figures or tables.

Submission Process

Manuscripts for Cancers should be submitted online at susy.mdpi.com. The submitting author, who is generally the corresponding author, is responsible for the manuscript during the submission and peer-review process. The submitting author must ensure that all eligible co-authors have been included in the author list (read the criteria to qualify for authorship) and that they have all read and approved the submitted version of the manuscript. To submit your manuscript, register and log in to the submission website. Once you have registered, click here to go to the submission form for Cancers. All co-authors can see the manuscript details in the submission system, if they register and log in using the e-mail address provided during manuscript submission.

Accepted File Formats

Authors must use the Microsoft Word template or LaTeX template to prepare their manuscript. Using the template file will substantially shorten the time to complete copy-editing and publication of accepted manuscripts. The total amount of data for all files must not exceed 120 MB. If this is a problem, please contact the Editorial Office [email protected]. Accepted file formats are:

  • Microsoft Word: Manuscripts prepared in Microsoft Word must be converted into a single file before submission. When preparing manuscripts in Microsoft Word, the Cancers Microsoft Word template file must be used. Please insert your graphics (schemes, figures, etc.) in the main text after the paragraph of its first citation.
  • LaTeX: Manuscripts prepared in LaTeX must be collated into one ZIP folder (including all source files and images, so that the Editorial Office can recompile the submitted PDF). When preparing manuscripts in LaTeX, please use the Cancers LaTeX template files. You can now also use the online application writeLaTeX to submit articles directly to Cancers. The MDPI LaTeX template file should be selected from the writeLaTeX template gallery.
  • Supplementary files: May be any format, but it is recommended that you use common, non-proprietary formats where possible (see below for further details).

Disclaimer: Usage of these templates is exclusively intended for submission to the journal for peer-review, and strictly limited to this purpose and it cannot be used for posting online on preprint servers or other websites.

Free Format Submission

Cancers now accepts free format submission:

  • We do not have strict formatting requirements, but all manuscripts must contain the required sections: Author Information, Abstract, Keywords, Introduction, Materials & Methods, Results, Conclusions, Figures and Tables with Captions, Funding Information, Author Contributions, Conflict of Interest and other Ethics Statements. Check the Journal Instructions for Authors for more details.
  • Your references may be in any style, provided that you use the consistent formatting throughout. It is essential to include author(s) name(s), journal or book title, article or chapter title (where required), year of publication, volume and issue (where appropriate) and pagination. DOI numbers (Digital Object Identifier) are not mandatory but highly encouraged. The bibliography software package EndNote, Zotero, Mendeley, Reference Manager are recommended.
  • When your manuscript reaches the revision stage, you will be requested to format the manuscript according to the journal guidelines.

Cover Letter

A cover letter must be included with each manuscript submission. It should be concise and explain why the content of the paper is significant, placing the findings in the context of existing work and why it fits the scope of the journal. Confirm that neither the manuscript nor any parts of its content are currently under consideration or published in another journal. Any prior submissions of the manuscript to MDPI journals must be acknowledged. The names of proposed and excluded reviewers should be provided in the submission system, not in the cover letter.

Author Biography

Authors are encouraged to add a biography (maximum 150 words) to the submission and publish it. This should be a single paragraph and should contain the following points:

  1. Authors’ full names followed by current positions;
  2. Education background including institution information and year of graduation (type and level of degree recieved);
  3. Work experience;
  4. Current and previous research interests;
  5. Memberships of professional societies and awards received.

Note for Authors Funded by the National Institutes of Health (NIH)

This journal automatically deposits papers to PubMed Central after publication of an issue. Authors do not need to separately submit their papers through the NIH Manuscript Submission System (NIHMS, http://nihms.nih.gov/).

[Return to top]

Registered Reports

Registered Reports are scientific articles which are peer-reviewed before the research is performed and the data are collected.

The ideas that meet high scientific standards, such as rigor, soundness, significant importance and implications for the science community, are then provisionally accepted for publication before data collection starts.

This format helps to considerably reduce publication bias and to avoid researchers having to invest much time and effort into questionable research studies, while allowing enough flexibility to perform unregistered experiments and report serendipitous findings.

The review process for Registered Reports can be briefly summarize into two main stages.

Stage 1:

  •   Submission: Authors propose a clear hypothesis (including background, experimental methods and analyses) that they plan to investigate.
  •   Peer review: Reviewers evaluate the registered study proposal before data are collected (research importance, rigor, soundness, etc.)

Following in-principle acceptance (IPA), the authors are asked to perform the experiments, following exactly the peer-reviewed procedures.

Stage 2:

  •    Submission: Authors come back with a complete study, including the results and analyses.
  •    Peer review: Reviewers take another look, this time considering the full study and assessing compliance with the original protocol.

Guidelines for Authors

Registered Reports are a form of empirical article in which the methods and proposed analyses are pre-registered and reviewed prior to research being conducted. This format is designed to minimise bias in deductive science, while also allowing complete flexibility to conduct exploratory (unregistered) analyses and report serendipitous findings.

The cornerstone of the Registered Reports format is that a significant part of the manuscript will be assessed prior to data collection, with the highest quality submissions accepted in advance. Initial submissions will include a description of the key research question and background literature, hypotheses, experimental procedures, analysis pipeline, a statistical power analysis (or Bayesian equivalent), and pilot data (where applicable).

Initial submissions will be triaged by an editorial team for suitability. Those that pass triage will then be sent for in-depth peer review (Stage 1). Following review, the article will then be either rejected or accepted in principle for publication. Following in principle acceptance (IPA), the authors will then proceed to conduct the study, adhering exactly to the peer-reviewed procedures. When the study is complete the authors will submit their finalised manuscript for re-review (Stage 2) and will upload their raw data, digital study materials, and laboratory log to a publicly accessible file-sharing service. Pending quality checks and a sensible interpretation of the findings, the manuscript will be published regardless of the results.

The review process for Registered Reports

Stage 1: Initial manuscript submission and review

Stage 1 submissions should include the manuscript (details below) and a brief cover letter. Please note that the editorial board will not agree to send manuscripts for in-depth review until a complete Stage 1 submission has been considered.

The title of the paper should include words “Stage 1”.

The Stage 1 cover letter should include:

  •    A brief scientific case for consideration. Authors are encouraged to refer to the likely replication value of the research. Replication studies are welcome in addition to novel studies.
  •    A statement confirming that all necessary support (e.g., funding, facilities) and approvals (e.g., ethics) are in place for the proposed research. Note that manuscripts will be generally considered only for studies that are able to commence immediately; however, authors with alternative plans are encouraged to contact the journal office for advice.
  •    An anticipated timeline (typically within 12 months) for completing the study if the initial submission is accepted. Authors should contact the Editorial team for advice if longer time is needed.
  •    A statement confirming that the authors agree to share their raw data, any digital study materials, and analysis code as appropriate.
  •    A statement confirming that, following Stage 1 in principle acceptance, the authors choose to publish Stage 1 papers in the journal.

Manuscript preparation guidelines – Stage 1

Initial Stage 1 submissions should include the following sections

  • Introduction
    • A review of the relevant literature that motivates the research question and a full description of the experimental aims and hypotheses. Please note that following IPA, the Introduction section cannot be altered apart from correction of factual errors, typographic errors and altering of tense from future to past (see below).
  • Methods
    • Full description of proposed sample characteristics, including criteria for data inclusion and exclusion (e.g., outlier extraction). Procedures for objectively defining exclusion criteria due to technical errors or for any other reasons must be specified, including details of how and under what conditions data would be replaced.
    • A description of experimental procedures in sufficient detail to allow another researcher to repeat the methodology exactly, without requiring further information. These procedures must be adhered to exactly in the subsequent experiments or any Stage 2 manuscript can be rejected.
    • Proposed analysis pipeline, including all preprocessing steps, and a precise description of all planned analyses, including appropriate correction for multiple comparisons. Any covariates or regressors must be stated. Where analysis decisions are contingent on the outcome of prior analyses, these contingencies must be specified and adhered to. Only pre-planned analyses can be reported in the main Results section of Stage 2 submissions. However, unplanned exploratory analyses will be admissible in a separate section of the Results (see below).
    • Studies involving Neyman-Pearson inference must include a statistical power analysis. Estimated effect sizes should be justified with reference to the existing literature or theory. Since publication bias overinflates published estimates of effect size, power analysis must be based on the lowest available or meaningful estimate of the effect size. For frequentist analysis plans, the a priori power must be 0.9 or higher for all proposed hypothesis tests. In the case of highly uncertain effect sizes, a variable sample size and interim data analysis is permissible but with inspection points stated in advance, appropriate Type I error correction for ‘peeking’ employed, and a final stopping rule for data collection outlined.
    • Methods involving Bayesian hypothesis testing are encouraged. For studies involving analyses with Bayes factors, the predictions of the theory must be specified so that a Bayes factor can be calculated. Authors should indicate what distribution will be used to represent the predictions of the theory and how its parameters will be specified. For example, will you use a uniform up to some specified maximum, or a normal/half-normal to represent a likely effect size, or a JZS/Cauchy with a specified scaling constant? For inference by Bayes factors, authors must be able to guarantee data collection until the Bayes factor is at least 6 times in favour of the experimental hypothesis over the null hypothesis (or vice versa). Authors with resource limitations are permitted to specify a maximum feasible sample size at which data collection must cease regardless of the Bayes factor; however to be eligible for advance acceptance this number must be sufficiently large that inconclusive results at this sample size would nevertheless be an important message for the field. For further advice on Bayes factors or Bayesian sampling methods, prospective authors are encouraged to read this key article by Schönbrodt and Wagenmakers.
    • Full descriptions must be provided of any outcome-neutral criteria that must be met for successful testing of the stated hypotheses. Such quality checks might include the absence of floor or ceiling effects in data distributions, positive controls, or other quality checks that are orthogonal to the experimental hypotheses.
    • A timeline for completion of the study and proposed resubmission date if Stage 1 review is successful must be included. Extensions to this deadline can be negotiated with the Editorial Team.
    • Any description of prospective methods or analysis plans should be written in future tense.
  • Pilot Data
    • Optional. Can be included to establish proof of concept, effect size estimations, or feasibility of proposed methods. Any pilot experiments will be published with the final version of the manuscript and will be clearly distinguished from data obtained for the pre-registered experiment(s).
  • Secondary Registrations
    • The journal welcomes submissions proposing secondary analyses of existing data sets, provided authors can supply sufficient evidence (e.g., self-certification; letter from independent gatekeeper) to confirm that they have had no prior access to the data in question. For advice on the eligibility of specific scenarios, authors are welcome to contact the editorial office.

Stage 1 submissions that are judged by the editorial board to be of sufficient quality and within journal scope will be sent for in-depth peer review. In considering papers at the registration stage, reviewers will be asked to assess:

1. The importance and soundness of the proposed hypotheses
2. The suitabilty and feasibility of the experimental and analysis methodology
3. Whether there are sufficient details given to replicate the proposed experimental procedures and analysis
4. Whether there are sufficient outcome-neutral tests of the hypotheses, including positive controls and quality checks

Following Stage 1 peer review, manuscripts will be rejected outright, offered the opportunity to revise, or accepted. Proposals that exceed the highest standards of importance and scientific rigour will be issued an in principle acceptance (IPA), indicating that the article will be published pending completion of the approved methods and analytic procedures, passing of all pre-specified quality checks, and a defensible interpretation of the results. Manuscripts that pass Stage 1 peer review will be published immediately. Authors will be required to cite Stage 1 papers in the final Stage 2 manusripts and link it to Stage 1, indicating the manuscript is a registered report.

Authors are reminded that any deviation from the stated experimental procedures, regardless of how minor it may seem to the authors, could lead to rejection of the manuscript at Stage 2. In cases where the pre-registered protocol is altered after IPA due to unforeseen circumstances (e.g., change of equipment or unanticipated technical error), the authors must consult the editorial team immediately for advice, and prior to the completion of data collection. Minor changes to the protocol may be permitted per editorial discretion. In such cases, IPA would be preserved and the deviation reported in the Stage 2 submission. Note that registered analyses must be undertaken, but additional unregistered analyses can also be included in a final manuscript (see below).

Stage 2: Full manuscript review

Once the study is complete, authors prepare and resubmit their manuscript for full review, with the following additions:

  • The title of the paper should include words “Stage 2”.
  • Cover letter. The Stage 2 cover letter must confirm:
    • o    That the manuscript includes a link to the published Stage 1 paper, or to the public archive containing anonymized study data, digital materials/code and the laboratory log. The cover letter should state the page number in the manuscript that lists the URL.
    • o    That, for primary Registered Reports, no data for any pre-registered study (other than pilot data included at Stage 1) was collected prior to the date of IPA. For secondary Registered Reports, authors should confirm that no data (other than pilot data included at Stage 1) was subjected to the pre-registered analyses prior to IPA.
  • Submission of anonymised raw data, digital study materials, and laboratory log
    • o    Anonymised raw data and digital study materials must be made freely available in a public repository/archive with a link provided within the Stage 2 manuscript. Authors are free to use any repository that renders data and materials freely and publicly accessible and provides a digital object identifier (DOI) to ensure that the data remain persistent, unique and citable. Potential repositories include (but are not limited to), Figshare, Harvard Dataverse, and Dryad. For a comprehensive list of available data repositories, see http://www.re3data.org/.
    • Data files should be appropriately time stamped to show that data was collected after IPA and not before. Other than pre-registered and approved pilot data, no data acquired priorto the date of IPA is admissible in the Stage 2 submission. Raw data must be accompanied by guidance notes, where required, to assist other scientists in replicating the analysis pipeline. Authors are required to upload any relevant analysis scripts and other digital experimental materials that would assist in replication.
    • Any supplementary figures, tables, or other text (such as supplementary methods) can either be included as standard supplementary information that accompanies the paper, or they can be archived together with the data. Please note that the raw data itself should be archived (see above) rather than submitted to the journal as supplementary material.
    • A basic laboratory log must also be provided outlining the range of dates during which data collection took place. This log should be uploaded to the same public archive as the data and materials.
  • Background, Rationale and Methods
    • Apart from minor stylistic revisions, the Introduction cannot be altered from the approved Stage 1 submission, and the stated hypotheses cannot be amended or appended. At Stage 2, any description of the rationale or proposed methodology that was written in future tense within the Stage 1 manuscript should be changed to past tense. Any textual changes to the Introduction or Methods (e.g. correction of typographic errors) must be clearly marked in the Stage 2 submission. Any relevant literature that appeared following the date of IPA should be covered in the Discussion.
  • Results & Discussion
    • The outcome of all registered analyses must be reported in the manuscript, except in rare instances where a registered and approved analysis is subsequently shown to be logically flawed or unfounded. In such cases, the authors, reviewers, and editor must agree that a collective error of judgment was made and that the analysis is inappropriate. In such cases the analysis would still be mentioned in the Methods but omitted with justification from the Results.
    • It is reasonable that authors may wish to include additional analyses that were not included in the registered submission. For instance, a new analytic approach might become available between IPA and Stage 2 review, or a particularly interesting and unexpected finding may emerge. Such analyses are admissible but must be clearly justified in the text, appropriately caveated, and reported in a separate section of the Results titled “Exploratory Analyses”. Authors should be careful not to base their conclusions entirely on the outcome of statistically significant post hoc analyses.
    • Authors reporting null hypothesis significance tests are required to report exact p values and effect sizes for all inferential analyses.

The resubmission will most likely be considered by the same reviewers as in Stage 1, but could also be assessed by new reviewers. In considering papers at Stage 2, reviewers will be asked to decide:

  1. Whether the data are able to test the original proposed hypotheses by satisfying the approved outcome-neutral conditions (such as quality checks, positive controls)
  2. Whether the stated hypotheses tested was the same as the approved Stage 1 submission
  3. Whether the authors adhered precisely to the registered experimental procedures or were able to sufficiently justify any changes
  4. Whether any new analyses (not mentioned at Stage 1) are methodologically sound and relevant
  5. Whether the authors’ conclusions are justified given the data

Reviewers are informed that editorial decisions will not be based on the perceived importance, novelty or conclusiveness of the results. Thus, while reviewers are free to enter such comments on the record, they will not influence editorial decisions. Reviewers at Stage 2 may suggest that authors report additional post hoc tests on their data; however, authors are not obliged to do so unless such tests are necessary to satisfy one or more of the Stage 2 review criteria.

Manuscript withdrawal

It is possible that authors with IPA may wish to withdraw their manuscript following or during data collection. Possible reasons could include major technical error, an inability to complete the study due to other unforeseen circumstances, or the desire to submit the results to a different journal. In all such cases, manuscripts can of course be withdrawn at the authors’ discretion.

Incremental Registrations

Authors may add experiments to approved submissions. In such cases the approved Stage 2 manuscript will be accepted for publication, and authors can propose additional experiments for Stage 1 consideration. Where these experiments extend the approved submission (as opposed to being part of new submissions), the editorial team will seek to fast-track the review process. This option may be particularly appropriate where an initial experiment reveals a major serendipitous finding that warrants follow-up within the same paper. In cases where an incremented submission is rejected (at either Stage 1 or 2), authors will retain the option of publishing the most recently approved version of the manuscript. For further advice on specific scenarios for incremental registration, authors are invited to contact the editorial office.

Tips for Avoiding Desk Rejection at Stage 1

Many Registered Report submissions are desk rejected at Stage 1, prior to in-depth review, for failing to sufficiently meet the Stage 1 editorial criteria. In many such cases, authors are invited to resubmit once specific shortcomings are addressed, although major problems can lead to outright rejection. To help minimize the chances of authors’ submissions being desk rejected, we list below the top ten reasons why Stage 1 submissions are rejected prior to review.

  1. Cover letter doesn’t make necessary statements concerning ethics, data archiving, and so forth (see above).
  2. The protocol contains insufficient methodological detail to enable replication and prevent researcher degrees of freedom. One commonly neglected area is the criteria for excluding data, both at the level of animals/participants and at the level of data within animals/participants. In the interests of clarity, we recommend listing these criteria systematically rather than presenting them in prose.
  3. Lack of correspondence between the scientific hypotheses and the pre-registered statistical tests. This is a common problem and severe cases are likely to be desk rejected outright. To maximize clarity of correspondence between predictions and analyses, authors are encouraged to number their hypotheses in the Introduction and then number the proposed analyses in the Methods to make clear which analysis tests which prediction. Ensure also that power analysis, where applicable, is based on the actual test procedures that will be employed to test those hypotheses; e.g. don’t propose a power analysis based on an ANOVA but then suggest a linear mixed effects model to test the hypothesis.
  4. Power analysis, where applicable, fails to reach the minimum level stated in journal policy.
  5. Power analysis is over-optimistic (e.g. based on previous literature but not taking into account publication bias) or insufficiently justified (e.g. based on a single point estimate from a pilot experiment or previous study). Proposals should be powered to detect the smallest effect that is plausible and of theoretical value. Pilot data can help inform this estimate but is unlikely to form an acceptable basis, alone, for choosing the target effect size.
  6. Intention to infer support for the null hypothesis from statistically non-significant results, without proposing use of Bayes factors or frequentist equivalence testing.
  7. Inclusion of exploratory analyses in the analysis plan. Manuscripts proposing exploratory analyses will usually be desk rejected until such analyses are removed because inclusion of exploratory “plans” at Stage 1 blurs the line between confirmatory and exploratory outcomes at Stage 2. Instead, such analyses can be included at Stage 2 and need not be pre-registered. Under some circumstances, exploratory analyses could be discussed at Stage 1 where they are necessary to justify study variables or procedures that are included in the design exclusively for exploratory analysis.
  8. Failure to clearly distinguish work that has already been done from work that is planned. Where a proposal contains a mixture of pilot work that has already been undertaken and a proposal for work not yet undertaken, authors should use the past tense for pilot work but the future tense for the proposed work. At Stage 2, all descriptions shift to past tense.
  9. Lack of pre-specified positive controls or other quality checks, or an appropriate justification for their absence (See Stage 1 criterion 5). We recognise that positive controls are not possible with all study designs, in which case authors should discuss why they are not included.
  10. Where applicable, lack of power analysis within proposed positive controls that depend on hypothesis testing.

[Return to top]

Manuscript Preparation

General Considerations

  • Research manuscripts should comprise:
  • Review manuscripts should comprise the front matter, literature review sections and the back matter. The template file can also be used to prepare the front and back matter of your review manuscript. It is not necessary to follow the remaining structure. Structured reviews and meta-analyses should use the same structure as research articles and ensure they conform to the PRISMA guidelines.
  • Case Reports are not considered in the journal.
  • Graphical Abstract:

    A graphical abstract (GA) is an image that appears alongside the text abstract in the Table of Contents. In addition to summarizing content, it should represent the topic of the article in an attention-grabbing way.

    The GA should be a high-quality illustration or diagram in any of the following formats: PNG, JPEG, EPS, SVG, PSD or AI. Written text in a GA should be clear and easy to read, using one of the following fonts: Times, Arial, Courier, Helvetica, Ubuntu or Calibri.

    The minimum required size for the GA is 560 × 1100 pixels (height × width). When submitting larger images, please make sure to keep to the same ratio.

  • Video abstract: Authors are encouraged to provide a video abstract. A video abstract is a motion picture equivalent of a written abstract and aims to increase the visibility of authors’ research. Video abstracts should be engaging and interesting and offer viewers more information than could be written in a textual abstract. The video file must be MP4 format and should not exceed 200 MB. The preferred length of video abstracts is 5 minutes or less.
  • Abbreviations should be defined in parentheses the first time they appear in the abstract, main text, and in figure or table captions and used consistently thereafter.
  • SI Units (International System of Units) should be used. Imperial, US customary and other units should be converted to SI units whenever possible.
  • Accession numbers of RNA, DNA and protein sequences used in the manuscript should be provided in the Materials and Methods section. Also see the section on Deposition of Sequences and of Expression Data.
  • Equations: If you are using Word, please use either the Microsoft Equation Editor or the MathType add-on. Equations should be editable by the editorial office and not appear in a picture format.
  • Research Data and supplementary materials: Note that publication of your manuscript implies that you must make all materials, data, and protocols associated with the publication available to readers. Disclose at the submission stage any restrictions on the availability of materials or information. Read the information about Supplementary Materials and Data Deposit for additional guidelines.
  • Preregistration: Where authors have preregistered studies or analysis plans, links to the preregistration must be provided in the manuscript.
  • Guidelines and standards: MDPI follows standards and guidelines for certain types of research. See https://www.mdpi.com/editorial_process for further information.

[Return to top]

Front Matter

These sections should appear in all manuscript types

  • Title: The title of your manuscript should be concise, specific and relevant. It should identify if the study reports (human or animal) trial data, or is a systematic review, meta-analysis or replication study. When gene or protein names are included, the abbreviated name rather than full name should be used.
  • Author List and Affiliations: Authors' full first and last names must be provided. The initials of any middle names can be added. The PubMed/MEDLINE standard format is used for affiliations: complete address information including city, zip code, state/province, and country. At least one author should be designated as corresponding author, and his or her email address and other details should be included at the end of the affiliation section. Please read the criteria to qualify for authorship.
  • Simple Summary: It should be written in one paragraph before the Abstract, in layman’s terms, to explain why the research is being suggested, what the authors aim to achieve, and how the findings from this research may impact the research community. Please use as few abbreviations as possible, and do not cite references in the Simple Summary. The Simple Summary should not exceed 150 words. Submissions without a simple summary will be returned directly. An example can be found at https://www.mdpi.com/2072-6694/12/9/2424.
  • Abstract: The abstract should be a total of about 200 words maximum. The abstract should be a single paragraph and should follow the style of structured abstracts, but without headings: 1) Background: Place the question addressed in a broad context and highlight the purpose of the study; 2) Methods: Describe briefly the main methods or treatments applied. Include any relevant preregistration numbers, and species and strains of any animals used. 3) Results: Summarize the article's main findings; and 4) Conclusion: Indicate the main conclusions or interpretations. The abstract should be an objective representation of the article: it must not contain results which are not presented and substantiated in the main text and should not exaggerate the main conclusions.
  • Keywords: Three to ten pertinent keywords need to be added after the abstract. We recommend that the keywords are specific to the article, yet reasonably common within the subject discipline.

Research Manuscript Sections

  • Introduction: The introduction should briefly place the study in a broad context and highlight why it is important. It should define the purpose of the work and its significance, including specific hypotheses being tested. The current state of the research field should be reviewed carefully and key publications cited. Please highlight controversial and diverging hypotheses when necessary. Finally, briefly mention the main aim of the workand highlight the main conclusions. Keep the introduction comprehensible to scientists working outside the topic of the paper.
  • Results: Provide a concise and precise description of the experimental results, their interpretation as well as the experimental conclusions that can be drawn.
  • Discussion: Authors should discuss the results and how they can be interpreted in perspective of previous studies and of the working hypotheses. The findings and their implications should be discussed in the broadest context possible and limitations of the work highlighted. Future research directions may also be mentioned. This section may be combined with Results.
  • Materials and Methods: They should be described with sufficient detail to allow others to replicate and build on published results. New methods and protocols should be described in detail while well-established methods can be briefly described and appropriately cited. Give the name and version of any software used and make clear whether computer code used is available. Include any pre-registration codes.
  • Conclusions: This section is mandatory, with one or two paragraphs to end the main text.
  • Patents: This section is not mandatory, but may be added if there are patents resulting from the work reported in this manuscript.

[Return to top]

Back Matter

  • Supplementary Materials: Describe any supplementary material published online alongside the manuscript (figure, tables, video, spreadsheets, etc.). Please indicate the name and title of each element as follows Figure S1: title, Table S1: title, etc. For all Western blot figures, please include densitometry readings/intensity ratio of each band. In addition, please include the whole blot showing all the bands with all molecular weight markers on the Western in the Supplemental Materials.
  • Acknowledgments: All sources of funding of the study should be disclosed. Clearly indicate grants that you have received in support of your research work and if you received funds to cover publication costs. Note that some funders will not refund article processing charges (APC) if the funder and grant number are not clearly and correctly identified in the paper. Funding information can be entered separately into the submission system by the authors during submission of their manuscript. Such funding information, if available, will be deposited to FundRef if the manuscript is finally published.
  • Author Contributions: Each author is expected to have made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; or have drafted the work or substantively revised it; AND has approved the submitted version (and version substantially edited by journal staff that involves the author’s contribution to the study); AND agrees to be personally accountable for the author’s own contributions and for ensuring that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and documented in the literature.
    For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used "Conceptualization, X.X. and Y.Y.; Methodology, X.X.; Software, X.X.; Validation, X.X., Y.Y. and Z.Z.; Formal Analysis, X.X.; Investigation, X.X.; Resources, X.X.; Data Curation, X.X.; Writing – Original Draft Preparation, X.X.; Writing – Review & Editing, X.X.; Visualization, X.X.; Supervision, X.X.; Project Administration, X.X.; Funding Acquisition, Y.Y.”, please turn to the CRediT taxonomy for the term explanation. For more background on CRediT, see here. "Authorship must include and be limited to those who have contributed substantially to the work. Please read the section concerning the criteria to qualify for authorship carefully".
  • Conflicts of Interest: Authors must identify and declare any personal circumstances or interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. If there is no conflict of interest, please state "The authors declare no conflict of interest." Any role of the funding sponsors in the choice of research project; design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results must be declared in this section. Cancers does not publish studies funded by the tobacco industry. Any projects funded by pharmaceutical or food industries must pay special attention to the full declaration of funder involvement. If there is no role, please state “The sponsors had no role in the design, execution, interpretation, or writing of the study”. For more details please see Conflict of Interest.
  • References: References must be numbered in order of appearance in the text (including table captions and figure legends) and listed individually at the end of the manuscript. We recommend preparing the references with a bibliography software package, such as EndNote, ReferenceManager or Zotero to avoid typing mistakes and duplicated references. We encourage citations to data, computer code and other citable research material. If available online, you may use reference style 9. below.
  • Citations and References in Supplementary files are permitted provided that they also appear in the main text and in the reference list.

In the text, reference numbers should be placed in square brackets [ ], and placed before the punctuation; for example [1], [1–3] or [1,3]. For embedded citations in the text with pagination, use both parentheses and brackets to indicate the reference number and page numbers; for example [5] (p. 10). or [6] (pp. 101–105).

The reference list should include the full title, as recommended by the ACS style guide. Style files for Endnote and Zotero are available.

References should be described as follows, depending on the type of work:

  • Journal Articles:
    1. Author 1, A.B.; Author 2, C.D. Title of the article. Abbreviated Journal Name Year, Volume, page range.
  • Books and Book Chapters:
    2. Author 1, A.; Author 2, B. Book Title, 3rd ed.; Publisher: Publisher Location, Country, Year; pp. 154–196.
    3. Author 1, A.; Author 2, B. Title of the chapter. In Book Title, 2nd ed.; Editor 1, A., Editor 2, B., Eds.; Publisher: Publisher Location, Country, Year; Volume 3, pp. 154–196.
  • Unpublished work, submitted work, personal communication:
    4. Author 1, A.B.; Author 2, C. Title of Unpublished Work. status (unpublished; manuscript in preparation).
    5. Author 1, A.B.; Author 2, C. Title of Unpublished Work. Abbreviated Journal Name stage of publication (under review; accepted; in press).
    6. Author 1, A.B. (University, City, State, Country); Author 2, C. (Institute, City, State, Country). Personal communication, Year.
  • Conference Proceedings:
    7. Author 1, A.B.; Author 2, C.D.; Author 3, E.F. Title of Presentation. In Title of the Collected Work (if available), Proceedings of the Name of the Conference, Location of Conference, Country, Date of Conference; Editor 1, Editor 2, Eds. (if available); Publisher: City, Country, Year (if available); Abstract Number (optional), Pagination (optional).
  • Thesis:
    8. Author 1, A.B. Title of Thesis. Level of Thesis, Degree-Granting University, Location of University, Date of Completion.
  • Websites:
    9. Title of Site. Available online: URL (accessed on Day Month Year).
    Unlike published works, websites may change over time or disappear, so we encourage you create an archive of the cited website using a service such as WebCite. Archived websites should be cited using the link provided as follows:
    10. Title of Site. URL (archived on Day Month Year).

  • See the Reference List and Citations Guide for more detailed information.

    [Return to top]

    Preparing Figures, Schemes and Tables

    • File for Figures and Schemes must be provided during submission in a single zip archive and at a sufficiently high resolution (minimum 1000 pixels width/height, or a resolution of 300 dpi or higher). Common formats are accepted, however, TIFF, JPEG, EPS and PDF are preferred.
    • Cancers can publish multimedia files in articles or as supplementary materials. Please contact the editorial office for further information.
    • All Figures, Schemes and Tables should be inserted into the main text close to their first citation and must be numbered following their number of appearance (Figure 1, Scheme I, Figure 2, Scheme II, Table 1, etc.).
    • All Figures, Schemes and Tables should have a short explanatory title and caption.
    • All table columns should have an explanatory heading. To facilitate the copy-editing of larger tables, smaller fonts may be used, but no less than 8 pt. in size. Authors should use the Table option of Microsoft Word to create tables.
    • Authors are encouraged to prepare figures and schemes in color (RGB at 8-bit per channel). There is no additional cost for publishing full color graphics.

    [Return to top]

    Supplementary Materials, Data Deposit and Software Source Code

    MDPI Research Data Policies

    MDPI is committed to supporting open scientific exchange and enabling our authors to achieve best practices in sharing and archiving research data. We encourage all authors of articles published in MDPI journals to share their research data. Individual journal guidelines can be found at the journal ‘Instructions for Authors’ page. Data sharing policies concern the minimal dataset that supports the central findings of a published study. Generated data should be publicly available and cited in accordance with journal guidelines.

    MDPI data policies are informed by TOP Guidelines.

    Where ethical, legal or privacy issues are present, data should not be shared. The authors should make any limitations clear in the Data Availability Statement upon submission. Authors should ensure that data shared are in accordance with consent provided by participants on the use of confidential data.

    Data Availability Statements provide details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or generated during the study.

    Below are suggested Data Availability Statements:

    • Data available in a publicly accessible repository
      The data presented in this study are openly available in [repository name e.g., FigShare] at [doi], reference number [reference number].
    • Data available in a publicly accessible repository that does not issue DOIs
      Publicly available datasets were analyzed in this study. This data can be found here: [link/accession number]
    • Data available on request due to restrictions eg privacy or ethical
      The data presented in this study are available on request from the corresponding author. The data are not publicly available due to [insert reason here]
    • 3rd Party Data
      Restrictions apply to the availability of these data. Data was obtained from [third party] and are available [from the authors / at URL] with the permission of [third party].
    • Data sharing not applicable
      No new data were created or analyzed in this study. Data sharing is not applicable to this article.
    • Data is contained within the article or supplementary material
      The data presented in this study are available in [insert article or supplementary material here]

    Data citation:

    • [dataset] Authors. Year. Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g., DOI).

    Computer Code and Software

    For work where novel computer code was developed, authors should release the code either by depositing in a recognized, public repository or uploading as supplementary information to the publication. The name and version of all software used should be clearly indicated.

    Supplementary Material

    Additional data and files can be uploaded as "Supplementary Files" during the manuscript submission process. The supplementary files will also be available to the referees as part of the peer-review process. Any file format is acceptable, however we recommend that common, non-proprietary formats are used where possible.

    Unpublished Data

    Restrictions on data availability should be noted during submission and in the manuscript. "Data not shown" should be avoided: authors are encouraged to publish all observations related to the submitted manuscript as Supplementary Material. "Unpublished data" intended for publication in a manuscript that is either planned, "in preparation" or "submitted" but not yet accepted, should be cited in the text and a reference should be added in the References section. "Personal Communication" should also be cited in the text and reference added in the References section. (see also the MDPI reference list and citations style guide).

    Remote Hosting and Large Data Sets

    Data may be deposited with specialized service providers or institutional/subject repositories, preferably those that use the DataCite mechanism. Large data sets and files greater than 60 MB must be deposited in this way. For a list of other repositories specialized in scientific and experimental data, please consult databib.org or re3data.org. The data repository name, link to the data set (URL) and accession number, doi or handle number of the data set must be provided in the paper. The journal Data also accepts submissions of data set papers.

    Deposition of Sequences and of Expression Data

    New sequence information must be deposited to the appropriate database prior to submission of the manuscript. Accession numbers provided by the database should be included in the submitted manuscript. Manuscripts will not be published until the accession number is provided.

    • New nucleic acid sequences must be deposited in one of the following databases: GenBank, EMBL, or DDBJ. Sequences should be submitted to only one database.
    • New high throughput sequencing (HTS) datasets (RNA-seq, ChIP-Seq, degradome analysis, …) must be deposited either in the GEO database or in the NCBI’s Sequence Read Archive.
    • New microarray data must be deposited either in the GEO or the ArrayExpress databases.The "Minimal Information About a Microarray Experiment" (MIAME) guidelines published by the Microarray Gene Expression Data Society must be followed.
    • New protein sequences obtained by protein sequencing must be submitted to UniProt (submission tool SPIN).

    All sequence names and the accession numbers provided by the databases should be provided in the Materials and Methods section of the article.

    References in Supplementary Files

    Citations and References in Supplementary files are permitted provided that they also appear in the reference list of the main text.

    [Return to top]

    Research and Publication Ethics

    Research Ethics

    Research Involving Human Subjects

    When reporting on research that involves human subjects, human material, human tissues, or human data, authors must declare that the investigations were carried out following the rules of the Declaration of Helsinki of 1975 (https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/), revised in 2013. According to point 23 of this declaration, an approval from an ethics committee should have been obtained before undertaking the research. At a minimum, a statement including the project identification code, date of approval, and name of the ethics committee or institutional review board should be cited in the Methods Section of the article. Data relating to individual participants must be described in detail, but private information identifying participants need not be included unless the identifiable materials are of relevance to the research (for example, photographs of participants’ faces that show a particular symptom). Editors reserve the right to reject any submission that does not meet these requirements.

    Example of an ethical statement: "All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of XXX (Project identification code)."

    A written informed consent for publication must be obtained from participating patients who can be identified (including by the patients themselves). Patients’ initials or other personal identifiers must not appear in any images. For manuscripts that include any case details, personal information, and/or images of patients, authors must obtain signed informed consent from patients (or their relatives/guardians) before submitting to an MDPI journal. Patient details must be anonymized as far as possible, e.g., do not mention specific age, ethnicity, or occupation where they are not relevant to the conclusions. A template permission form is available to download. A blank version of the form used to obtain permission (without the patient names or signature) must be uploaded with your submission.

    You may refer to our sample form and provide an appropriate form after consulting with your affiliated institution. Alternatively, you may provide a detailed justification of why informed consent is not necessary. For the purposes of publishing in MDPI journals, a consent, permission, or release form should include unlimited permission for publication in all formats (including print, electronic, and online), in sublicensed and reprinted versions (including translations and derived works), and in other works and products under open access license. To respect patients’ and any other individual’s privacy, please do not send signed forms. The journal reserves the right to ask authors to provide signed forms if necessary.

    Ethical Guidelines for the Use of Animals in Research

    The editors will require that the benefits potentially derived from any research causing harm to animals are significant in relation to any cost endured by animals, and that procedures followed are unlikely to cause offense to the majority of readers. Authors should particularly ensure that their research complies with the commonly-accepted '3Rs':

    • Replacement of animals by alternatives wherever possible,
    • Reduction in number of animals used, and
    • Refinement of experimental conditions and procedures to minimize the harm to animals.

    Any experimental work must also have been conducted in accordance with relevant national legislation on the use of animals for research. For further guidance authors should refer to the Code of Practice for the Housing and Care of Animals Used in Scientific Procedures [1].

    Manuscripts containing original descriptions of research conducted in experimental animals must contain details of approval by a properly constituted research ethics committee. As a minimum, the project identification code, date of approval and name of the ethics committee or institutional review board should be cited in the Methods section.

    Cancers endorses the ARRIVE guidelines (www.nc3rs.org.uk/ARRIVE) for reporting experiments using live animals. Authors and reviewers can use the ARRIVE guidelines as a checklist, which can be found at www.nc3rs.org.uk/ARRIVEchecklist.

    1. Home Office. Animals (Scientific Procedures) Act 1986. Code of Practice for the Housing and Care of Animals Used in Scientific Procedures. Available online: http://www.official-documents.gov.uk/document/hc8889/hc01/0107/0107.pdf.

    Research Involving Cell Lines

    Methods sections for submissions reporting on research with cell lines should state the origin of any cell lines. For established cell lines the provenance should be stated and references must also be given to either a published paper or to a commercial source. If previously unpublished de novo cell lines were used, including those gifted from another laboratory, details of institutional review board or ethics committee approval must be given, and confirmation of written informed consent must be provided if the line is of human origin.

    An example of Ethical Statements:

    The HCT116 cell line was obtained from XXXX. The MLH1+ cell line was provided by XXXXX, Ltd. The DLD-1 cell line was obtained from Dr. XXXX. The DR-GFP and SA-GFP reporter plasmids were obtained from Dr. XXX and the Rad51K133A expression vector was obtained from Dr. XXXX.

    Research Involving Plants

    Experimental research on plants (either cultivated or wild) including collection of plant material, must comply with institutional, national, or international guidelines. We recommend that authors comply with the Convention on Biological Diversity and the Convention on the Trade in Endangered Species of Wild Fauna and Flora.

    For each submitted manuscript supporting genetic information and origin must be provided. For research manuscripts involving rare and non-model plants (other than, e.g., Arabidopsis thaliana, Nicotiana benthamiana, Oriza sativa, or many other typical model plants), voucher specimens must be deposited in an accessible herbarium or museum. Vouchers may be requested for review by future investigators to verify the identity of the material used in the study (especially if taxonomic rearrangements occur in the future). They should include details of the populations sampled on the site of collection (GPS coordinates), date of collection, and document the part(s) used in the study where appropriate. For rare, threatened or endangered species this can be waived but it is necessary for the author to describe this in the cover letter.

    Editors reserve the rights to reject any submission that does not meet these requirements.

    An example of Ethical Statements:

    Torenia fournieri plants were used in this study. White-flowered Crown White (CrW) and violet-flowered Crown Violet (CrV) cultivars selected from ‘Crown Mix’ (XXX Company, City, Country) were kindly provided by Dr. XXX (XXX Institute, City, Country).

    Arabidopis mutant lines (SALKxxxx, SAILxxxx,…) were kindly provided by Dr. XXX , institute, city, country).

    Clinical Trials Registration

    Registration

    MDPI follows the International Committee of Medical Journal Editors (ICMJE) guidelines which require and recommend registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition of consideration for publication.

    Purely observational studies do not require registration. A clinical trial not only refers to studies that take place in a hospital or involve pharmaceuticals, but also refer to all studies which involve participant randomization and group classification in the context of the intervention under assessment.

    Authors are required to pre-register clinical trials with an international clinical trials register and cite a reference to the registration in the abstract and Methods section. Suitable databases include clinicaltrials.gov, the EU Clinical Trials Register and those listed by the World Health Organisation International Clinical Trials Registry Platform.

    Approval to conduct a study from an independent local, regional, or national review body is not equivalent to prospective clinical trial registration. MDPI reserves the right to decline any paper without trial registration for further peer-review. However, if the study protocol has been published before the enrolment, the registration can be waived with correct citation of the published protocol.

    CONSORT Statement

    MDPI requires a completed CONSORT 2010 checklist and flow diagram as a condition of submission when reporting the results of a randomized trial. Templates for these can be found here or on the CONSORT website (http://www.consort-statement.org) which also describes several CONSORT checklist extensions for different designs and types of data beyond two group parallel trials. At minimum, your article should report the content addressed by each item of the checklist.

    [Return to top]

    Borders and Territories

    Potential disputes over borders and territories may have particular relevance for authors in describing their research or in an author or editor correspondence address, and should be respected. Content decisions are an editorial matter and where there is a potential or perceived dispute or complaint, the editorial team will attempt to find a resolution that satisfies parties involved.

    MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    Publication Ethics Statement

    Cancers is a member of the Committee on Publication Ethics (COPE). We fully adhere to its Code of Conduct and to its Best Practice Guidelines.

    The editors of this journal enforce a rigorous peer-review process together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, image manipulation, inappropriate authorship credit, and the like, do arise. The editors of Cancers take such publishing ethics issues very seriously and are trained to proceed in such cases with a zero tolerance policy.

    Authors wishing to publish their papers in Cancers must abide to the following:

    • Any facts that might be perceived as a possible conflict of interest of the author(s) must be disclosed in the paper prior to submission.
    • Authors should accurately present their research findings and include an objective discussion of the significance of their findings.
    • Data and methods used in the research need to be presented in sufficient detail in the paper, so that other researchers can replicate the work.
    • Raw data should preferably be publicly deposited by the authors before submission of their manuscript. Authors need to at least have the raw data readily available for presentation to the referees and the editors of the journal, if requested. Authors need to ensure appropriate measures are taken so that raw data is retained in full for a reasonable time after publication.
    • Simultaneous submission of manuscripts to more than one journal is not tolerated.
    • Republishing content that is not novel is not tolerated (for example, an English translation of a paper that is already published in another language will not be accepted).
    • If errors and inaccuracies are found by the authors after publication of their paper, they need to be promptly communicated to the editors of this journal so that appropriate actions can be taken. Please refer to our policy regarding publication of publishing addenda and corrections.
    • Your manuscript should not contain any information that has already been published. If you include already published figures or images, please obtain the necessary permission from the copyright holder to publish under the CC-BY license. For further information, see the Rights and Permissions page.
    • Plagiarism, data fabrication and image manipulation are not tolerated.
      • Plagiarism is not acceptable in Cancers submissions.

        Plagiarism includes copying text, ideas, images, or data from another source, even from your own publications, without giving any credit to the original source.

        Reuse of text that is copied from another source must be between quotes and the original source must be cited. If a study's design or the manuscript's structure or language has been inspired by previous works, these works must be explicitly cited.

        If plagiarism is detected during the peer review process, the manuscript may be rejected. If plagiarism is detected after publication, we may publish a correction or retract the paper.

      • Image files must not be manipulated or adjusted in any way that could lead to misinterpretation of the information provided by the original image.

        Irregular manipulation includes: 1) introduction, enhancement, moving, or removing features from the original image; 2) grouping of images that should obviously be presented separately (e.g., from different parts of the same gel, or from different gels); or 3) modifying the contrast, brightness or color balance to obscure, eliminate or enhance some information.

        If irregular image manipulation is identified and confirmed during the peer review process, we may reject the manuscript. If irregular image manipulation is identified and confirmed after publication, we may correct or retract the paper.

      Our in-house editors will investigate any allegations of publication misconduct and may contact the authors' institutions or funders if necessary. If evidence of misconduct is found, appropriate action will be taken to correct or retract the publication. Authors are expected to comply with the best ethical publication practices when publishing with MDPI.

    Citation Policy

    Authors should ensure that where material is taken from other sources (including their own published writing) the source is clearly cited and that where appropriate permission is obtained.

    Authors should not engage in excessive self-citation of their own work.

    Authors should not copy references from other publications if they have not read the cited work.

    Authors should not preferentially cite their own or their friends’, peers’, or institution’s publications.

    Authors should not cite advertisements or advertorial material.

    In accordance with COPE guidelines, we expect that “original wording taken directly from publications by other researchers should appear in quotation marks with the appropriate citations.” This condition also applies to an author’s own work. COPE have produced a discussion document on citation manipulation with recommendations for best practice.

    [Return to top]

    Reviewer Suggestions

    During the submission process, please suggest three potential reviewers with the appropriate expertise to review the manuscript. The editors will not necessarily approach these referees. Please provide detailed contact information (address, homepage, phone, e-mail address). The proposed referees should neither be current collaborators of the co-authors nor have published with any of the co-authors of the manuscript within the last five years. Proposed reviewers should be from different institutions to the authors. You may identify appropriate Editorial Board members of the journal as potential reviewers. You may suggest reviewers from among the authors that you frequently cite in your paper.

    [Return to top]

    English Corrections

    To facilitate proper peer-reviewing of your manuscript, it is essential that it is submitted in grammatically correct English. Advice on some specific language points can be found here.

    If you are not a native English speaker, we recommend that you have your manuscript professionally edited before submission or read by a native English-speaking colleague. This can be carried out by MDPI's English editing service. Professional editing will enable reviewers and future readers to more easily read and assess the content of submitted manuscripts. All accepted manuscripts undergo language editing, however an additional fee will be charged to authors if very extensive English corrections must be made by the Editorial Office: pricing is according to the service here.

    [Return to top]

    Preprints and Conference Papers

    Cancers accepts submissions that have previously been made available as preprints provided that they have not undergone peer review. A preprint is a draft version of a paper made available online before submission to a journal.

    MDPI operates Preprints, a preprint server to which submitted papers can be uploaded directly after completing journal submission. Note that Preprints operates independently of the journal and posting a preprint does not affect the peer review process. Check the Preprints instructions for authors for further information.

    Expanded and high-quality conference papers can be considered as articles if they fulfill the following requirements: (1) the paper should be expanded to the size of a research article; (2) the conference paper should be cited and noted on the first page of the paper; (3) if the authors do not hold the copyright of the published conference paper, authors should seek the appropriate permission from the copyright holder; (4) authors are asked to disclose that it is conference paper in their cover letter and include a statement on what has been changed compared to the original conference paper. Cancers does not publish pilot studies or studies with inadequate statistical power.

    Unpublished conference papers that do not meet the above conditions are recommended to be submitted to the Proceedings series of journals:

    Proceedings: https://www.mdpi.com/journal/proceedings

    [Return to top]

    Authorship

    MDPI follows the International Committee of Medical Journal Editors (ICMJE) guidelines which state that, in order to qualify for authorship of a manuscript, the following criteria should be observed:

    • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
    • Drafting the work or revising it critically for important intellectual content; AND
    • Final approval of the version to be published; AND
    • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

    Those who contributed to the work but do not qualify for authorship should be listed in the acknowledgments. More detailed guidance on authorship is given by the International Council of Medical Journal Editors (ICMJE).

    Any change to the author list should be approved by all authors including any who have been removed from the list. The corresponding author should act as a point of contact between the editor and the other authors and should keep co-authors informed and involve them in major decisions about the publication. We reserve the right to request confirmation that all authors meet the authorship conditions.

    Reviewers Recommendation

    Authors can recommend potential reviewers. Journal editors will check to make sure there are no conflicts of interest before contacting those reviewers, and will not consider those with competing interests. Reviewers are asked to declare any conflicts of interest. Authors can also enter the names of potential peer reviewers they wish to exclude from consideration in the peer review of their manuscript, during the initial submission progress. The editorial team will respect these requests so long as this does not interfere with the objective and thorough assessment of the submission.

    Editors and Journal Staff as Authors

    Editorial independence is extremely important and MDPI does not interfere with editorial decisions.

    Editorial staff or editors shall not be involved in processing their own academic work. Submissions authored by editorial staff/editors will be assigned to at least two independent outside reviewers . Decisions will be made by other Editorial Board Members who do not have a conflict of interest with the author. Journal staff are not involved in the processing of their own work submitted to any MDPI journals.

    Conflict of Interests

    According to The International Committee of Medical Journal Editors, “Authors should avoid entering into agreements with study sponsors, both for-profit and non-profit, that interfere with authors’ access to all of the study’s data or that interfere with their ability to analyze and interpret the data and to prepare and publish manuscripts independently when and where they choose.”

    All authors must disclose all relationships or interests that could inappropriately influence or bias their work. Examples of potential conflicts of interest include but are not limited to financial interests (such as membership, employment, consultancies, stocks/shares ownership, honoraria, grants or other funding, paid expert testimonies and patent-licensing arrangements) and non-financial interests (such as personal or professional relationships, affiliations, personal beliefs).

    Authors can disclose potential conflicts of interest via the online submission system during the submission process. Declarations regarding conflicts of interest can also be collected via the MDPI disclosure form. The corresponding author must include a summary statement in the manuscript in a separate section “Conflicts of Interest” placed just before the reference list. The statement should reflect all the collected potential conflict of interest disclosures in the form.

    See below for examples of disclosures:

    Conflicts of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stocks in Company Y. Author C has been involved as a consultant and expert witness in Company Z. Author D is the inventor of patent X.

    If no conflicts exist, the authors should state:

    Conflicts of Interest: The authors declare no conflicts of interest.

    [Return to top]

    Editorial Procedures and Peer-Review

    Initial Checks

    All submitted manuscripts received by the Editorial Office will be checked by a professional in-house Managing Editor to determine whether they are properly prepared and whether they follow the ethical policies of the journal, including those for human and animal experimentation. Manuscripts that do not fit the journal's ethics policy or do not meet the standards of the journal will be rejected before peer-review. Manuscripts that are not properly prepared will be returned to the authors for revision and resubmission. After these checks, the Managing Editor will consult the journals’ Editor-in-Chief or Associate Editors to determine whether the manuscript fits the scope of the journal and whether it is scientifically sound. No judgment on the potential impact of the work will be made at this stage. Reject decisions at this stage will be verified by the Editor-in-Chief.

    Peer-Review

    Once a manuscript passes the initial checks, it will be assigned to at least two independent experts for peer-review. A single-blind review is applied, where authors' identities are known to reviewers. Peer review comments are confidential and will only be disclosed with the express agreement of the reviewer.

    In the case of regular submissions, in-house assistant editors will invite experts, including recommendations by an academic editor. These experts may also include Editorial Board Members and Guest Editors of the journal. Potential reviewers suggested by the authors may also be considered. Reviewers should not have published with any of the co-authors during the past five years and should not currently work or collaborate with any of the institutions of the co-authors of the submitted manuscript.

    Optional Open Peer-Review

    The journal operates optional open peer-review: Authors are given the option for all review reports and editorial decisions to be published alongside their manuscript. In addition, reviewers can sign their review, i.e., identify themselves in the published review reports. Authors can alter their choice for open review at any time before publication, but once the paper has been published changes will only be made at the discretion of the Publisher and Editor-in-Chief. We encourage authors to take advantage of this opportunity as proof of the rigorous process employed in publishing their research. To guarantee impartial refereeing, the names of referees will be revealed only if the referees agree to do so, and after a paper has been accepted for publication.

    Editorial Decision and Revision

    All the articles, reviews and communications published in MDPI journals go through the peer-review process and receive at least two reviews. The in-house editor will communicate the decision of the academic editor, which will be one of the following:

    • Accept after Minor Revisions:
      The paper is in principle accepted after revision based on the reviewer’s comments. Authors are given five days for minor revisions.
    • Reconsider after Major Revisions:
      The acceptance of the manuscript would depend on the revisions. The author needs to provide a point by point response or provide a rebuttal if some of the reviewer’s comments cannot be revised. Usually, only one round of major revisions is allowed. Authors will be asked to resubmit the revised paper within a suitable time frame, and the revised version will be returned to the reviewer for further comments.
    • Reject and Encourage Resubmission:
      If additional experiments are needed to support the conclusions, the manuscript will be rejected and the authors will be encouraged to re-submit the paper once further experiments have been conducted.
    • Reject:
      The article has serious flaws, and/or makes no original significant contribution. No offer of resubmission to the journal is provided.

    All reviewer comments should be responded to in a point-by-point fashion. Where the authors disagree with a reviewer, they must provide a clear response.

    Author Appeals

    Authors may appeal a rejection by sending an e-mail to the Editorial Office of the journal. The appeal must provide a detailed justification, including point-by-point responses to the reviewers' and/or Editor's comments. The Managing Editor of the journal will forward the manuscript and related information (including the identities of the referees) to the Editor-in-Chief, Associate Editor, or Editorial Board member. The academic Editor being consulted will be asked to give an advisory recommendation on the manuscript and may recommend acceptance, further peer-review, or uphold the original rejection decision. A reject decision at this stage is final and cannot be reversed.

    In the case of a special issue, the Managing Editor of the journal will forward the manuscript and related information (including the identities of the referees) to the Editor-in-Chief who will be asked to give an advisory recommendation on the manuscript and may recommend acceptance, further peer-review, or uphold the original rejection decision. A reject decision at this stage will be final and cannot be reversed.

    Production and Publication

    Once accepted, the manuscript will undergo professional copy-editing, English editing, proofreading by the authors, final corrections, pagination, and, publication on the www.mdpi.com website.

    [Return to top]

    Resource Identification Initiative

    To improve the reproducibility of scientific research, the Resource Identification Initiative aims to provide unique persistent identifiers for key biological resources, including antibodies, cell lines, model organisms and tools.

    We encourage authors to include unique identifiers - RRIDs- provided by the Resource Identification Portal in the dedicated section of the manuscript.

    To help authors quickly find the correct identifiers for their materials, there is a single website where all resource types can be found and a ‘cite this’ button next to each resource, that contains a proper citation text that should be included in the methods section of the manuscript.

    [Return to top]

    Back to TopTop